NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

How Genentech’s Collaboration Exit Has Changed the Investment Story at Adaptive Biotechnologies (ADPT)

On August 13, 2025, Genentech announced the termination of its Strategic Collaboration and License Agreement with Adaptive Biotechnologies, originally established to develop oncology cell therapy products, with an effective end date of February 9, 2026. This action releases Adaptive Biotechnologies from its exclusivity obligations in oncology cell therapies and is expected to result in the recognition of US$33.7 million in non-cash revenue in the second half of 2025. We'll explore how the...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Is Costco Stock Still Worth the Price After Strong Membership Renewals in 2025?

Thinking About Costco Wholesale Stock? Here's What You Need to Know Trying to decide whether to buy, sell, or simply hold onto Costco Wholesale stock? You are not alone. Even seasoned investors are giving this retail giant a fresh look, given how the stock has navigated both recent choppiness and impressive long-term gains. After all, this is a company whose loyal member base and strong business model have delivered some eye-catching returns, including nearly 9% in the past year and close to...